Trial Profile
A Phase 1, Multicenter, Open-Label, Dose Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (RHIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2020
Price :
$35
*
At a glance
- Drugs PNK 007 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation; Celularity
- 03 Apr 2019 Results assessing cell persistence, AML monitoring, and broader immune profiling by using data from this study presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 27 Feb 2018 Status changed from active, no longer recruiting to discontinued.